Keverprazan 14 days — Competitive Intelligence Brief

Keverprazan 14 days (Keverprazan 14 days) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: direct renin inhibitor. Area: Cardiovascular.

marketed direct renin inhibitor renin Cardiovascular Small molecule

Target snapshot

Keverprazan 14 days (Keverprazan 14 days) — Second Affiliated Hospital, School of Medicine, Zhejiang University. Keverprazan is a direct renin inhibitor.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Keverprazan 14 days TARGET	Keverprazan 14 days	Second Affiliated Hospital, School of Medicine, Zhejiang University	marketed	direct renin inhibitor	renin
Tekturna	ALISKIREN	Lxo Ireland	marketed	Renin Inhibitor	Renin	2007-01-01
Capozide 25/15	CAPTOPRIL	Aarxion Anda Hlding	marketed	Thiazide Diuretic [EPC]	Renin	1981-01-01
Early sequential nephron blockade	Early sequential nephron blockade	University of Parma	marketed	RAAS inhibitor combination strategy	Renin-angiotensin-aldosterone system (multiple targets)
Aliskiren Hydrochlorothiazide	Aliskiren Hydrochlorothiazide	Novartis	marketed	Direct renin inhibitor / thiazide diuretic combination	Renin; sodium-chloride cotransporter (NCCT)
ALIS	ALIS	Lxo Ireland	marketed		Multidrug resistance protein 1, Cytochrome P450 3A4, Renin
Aliskiren + Valsartan	Aliskiren + Valsartan	HeartDrug Research LLC	marketed	Direct renin inhibitor + angiotensin II receptor blocker combination	Renin and AT1 receptor

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (direct renin inhibitor class)

1. Second Affiliated Hospital, School of Medicine, Zhejiang University · 1 drug in this class